Evidence map›Paper›PMID 39995631›Full record

ReviewBiochemistry and biophysics reports2025

Apoptosis-inducing proteins with reduced expression in breast cancer: A review article.

Mohammad Mehdi Khaleghi, Faezeh Rouhi, Kourosh Eslami, Fatemeh Shafiee

Abstract readReview
In one paragraph

Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammad Mehdi KhaleghiDepartment of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Faezeh RouhiDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Kourosh EslamiBioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh ShafieeDepartment of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is considered one of the most abundant malignancies with high morbidity and mortality. Traditional cancer treatments possess various weaknesses, including a lack of specificity and numerous side effects. Novel cancer therapies aim to overcome the shortcomings of traditional therapies and offer more efficient and safe treatments. Designing and identifying novel proteins that can practically and specifically inhibit tumors by inducing apoptosis can interest researchers in this field. This review discusses recent studies on the use of four promising proteins, KAI1, Apoptin, BIF-1, and DFF-40, for breast cancer treatment. This study also focuses on alterations in the expression of the androgenic proteins and novel strategies for better penetration and delivery of these proteins. Lastly, prospects for protein-based targeted cancer therapy and future studies in this field are highlighted.

Indexed as

ApoptosisBreast neoplasmsDown-regulationGene expressionProteins

Identifiers

PMID39995631
PMCPMC11848494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.